David Wyatt

Chief Operating Officer at Aston Particle Technologies

David is a physical chemist (holding a PhD in Surface Chemistry and Colloid Science) with extensive medicine development experience. He spent 32 years with GlaxoSmithKline, in a range of increasingly senior scientific and management positions both in Research and Development and in Manufacturing. During that time, he and his teams assisted in the development of 5 respiratory medicines from molecule selection to be amongst today's gold standard treatments for asthma and chronic obstructive pulmonary disease.

His cv lists Evohaler™ pressurised Metered Dose Inhalers, Diskus™ and Ellipta™ Dry Powder Inhalers as well as intranasal and antiviral respiratory medicines. In his final position at GSK, which he held for 8 years, he was responsible for the technical aspects of respiratory new product introduction. His supply chain experience enhances his appreciation of the importance of maintaining product knowledge and hands-on experience in the provision of life-saving medicines.

He is now the Chief Operating Officer at Aston Particle Technologies Ltd a spin-out SME with a revolutionary new dispersion technology and he is an Honorary Professor of Pharmaceutical Sciences at Aston University. He is a past chair and board member of the Academy of Pharmaceutical Sciences UK.

David Wyatt Nov 2021_Biotech_Pharma_Summit_Profile_Gallery

Title: The development and supply of respiratory medicines